INNOVADERM CRO IS NOW INDERO.

Our Insights

FILTER BY:

Case Study

Urticaria Case Study

Case Study

Atopic Dermatitis (AD) Rescue Case Study

Case Study

A Success Story: Pre-IND and IND Support for an Alopecia Areata Investigational Product

Case Study

Plaque Psoriasis Case Study

Case Study

Nimbus Testimonial

Case Study

“Working with Indero for our alopecia areata trial has been a smooth and exceptional experience (…)” – An Inmagene Biopharmaceuticals Testimonial

Case Study

Success Story: Support for Vitiligo Pre-IND Submission and FDA Meeting Preparation

Case Study

Testimonial: “Thanks to Indero’s adaptive approach, we sailed through our trial with ease!”

Case Study

Indero, a Key Collaborator in Clinical and Study Development for Recently Published Phase 1 Atopic Dermatitis Study

Case Study

Generalized Pustular Psoriasis (GPP) Rescue Case Study

Case Study

Hidradenitis Suppurativa (HS) Case Study

Case Study

Palmoplantar Pustulosis (PPP) Case Study

Case Study

Notalgia Paresthetica (NP) Case Study

Case Study

Alopecia Areata (AA) Case Study

Case Study

Atopic Dermatitis (AD) Case Study

Case Study

Acne Case Study

FILTER BY:

News

Indero Celebrates 25 Years and Looks to the Future of Clinical Research

News

Indero is Returning to THE Annual USA Rheumatology Event!

News

Indero Showcasing Dermatology Expertise at EADV Congress in Paris

News

Meet Indero at SCDM 2025

News

Indero at EADV 2025—Supporting Innovation in Dermatology

News

Indero at ESDR 2025—Advancing Skin Science

News

Let’s Connect at the BIO 2025 convention in Boston!

News

Indero is heading to the European Dermatology Drug Development Summit 2025 in Berlin!

News

Join Us at EULAR 2025 in Barcelona!

FILTER BY:

Post

Key Sessions to Attend at ACR Convergence 2025

Post

EADV 2025’s Sessions You Cannot Miss

clinical outcome assessments in hidradenitis suppurativa
Post

Measuring Success: Navigating the Top 3 Clinical Outcome Assessments in Hidradenitis Suppurativa

Delayed Payments, Diminished Performance
Post

Delayed Payments, Diminished Performance: The Site Perspective

clinical outcome assessments in alopecia areata
Post

Measuring Success: Navigating the Top 3 Clinical Outcome Assessments in Alopecia Areata

Sponsor–Site Partnerships in Clinical Research
Post

Strengthening Sponsor–Site Partnerships in Clinical Research: Keys to Sustained Site Motivation and Operational Success

Building Trust and Long-Term Relationships in Clinical Trials
Post

Building Trust and Long-Term Relationships in Clinical Trials: A Guide for Biotech and Pharmaceutical Sponsors

risk based monitoring in clinical research
Post

From Theory to Practice: Breaking Down Risk-Based Monitoring in Clinical Trials

choose niche contract research organization
Post

Leveraging Specialized Knowledge: The Benefits of Niche CROs

FILTER BY:

White Paper

Centralized Monitoring: Exploring the Considerations and Challenges of Implementation

White Paper

Leveraging Technology in Phase I Clinical Trials

FILTER BY:

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Is Now

We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.